Audited Financial Results for the Half year and year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr Lalchandani Labs reported FY25 total income of Rs. 445.38 lacs, down from Rs. 504.50 lacs in FY24, a decline of roughly 12%. Net profit stood at Rs. 41.72 lacs versus Rs. 51.71 lacs last year, while EPS slipped to Rs. 0.96 from Rs. 1.43. The results include exceptional items of Rs. 119.01 lacs, including a one-time settlement (OTS) gain of Rs. 12.13 lacs from settling NPA loans with banks and NBFCs. The auditor (ATN & Co) issued a qualified opinion, flagging NPA status of loan accounts, defaults in principal and interest repayment despite holding significant cash, non-payment of statutory dues like PF, ESIC and TDS, and non-provision of gratuity and leave encashment liabilities. The auditor also added an emphasis of matter on missing balance confirmations and absence of provision for doubtful debts despite aged receivables.
This is a significant red flag for shareholders. The qualified audit opinion, NPA loan status, unpaid statutory dues, and declining core revenue point to serious financial stress, while exceptional items meaningfully inflate reported profits. Investors should be cautious as the true operational profitability is much weaker than the headline numbers suggest.